Investigating the effect of mountain Rosa canina L in the treatment of fatty liver

Capsule production containing Phytosomes carrying standardized Rosa canina L seed extract based on tiliroside separately and in combination with curcumin and catechins in patients with Non-Alcoholic Liver Disease (NAFLD)

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20100420003760N8

Enrollment

Registered

2024-01-23

Start date

2024-02-20

Completion date

Unknown

Last updated

2024-03-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-Alcoholic Liver Disease. Fatty (change of) liver, not elsewhere classified

Interventions

Intervention 1: Intervention group: receive the first dose (62 mg phytosome) of phytosome formulation containing Rosa Canina L. in addition to conventional treatment. The capsule will be taken orally

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Patients with sonographic findings of grade 1 to 3 fatty liver (or if possible based on fibroscan results)

Exclusion criteria

Exclusion criteria: Pregnant and lactating women Any finding of cirrhosis Hepatitis Pregnant and lactating women Fatty liver due to secondary causes such as alcohol consumption Taking hypoglycemic drugs Taking lipid-lowering drugs Taking anti-inflammatory drugs and any drugs affecting the liver People with kidney, respiratory, thyroid diseases Having a history of weight loss (more than 5% in the last 6 months) or bariatric surgery Participation in other studies related to clinical trials

Design outcomes

Primary

Measure	Time frame
Fatty liver grade. Timepoint: Before, and after intervention. Fibroscan time 0 and 360. Method of measurement: Through Questionnaire and Fibroscan.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMarzieh Rashidipour

Khoram-Abad University of Medical Sciences

m_rashidi80@yahoo.com+98 66 3320 4005

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026